Vertex has opened another front in its attempt to treat a rare cause of muscle weakness, paying Entrada Therapeutics $224 million upfront for the preclinical prospect ENTR-701.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,